In mouse models, after KRAS inactivation, one-third of spontaneous tumor recurrences that escape KRASG12D dependency shows deficit of KRAS expression and YAP1 amplification, resulting in an aggressive quasi-mesenchymal phenotype with the activation of cell cycle and DNA repair pathways through cooperation of the transcription factor E2F [10]. Here, KRAS is linked to neoplasm.